Literature DB >> 7139610

Response to estrogen by the human mammary carcinoma cell line CAMA-1.

B S Leung, S Qureshi, J S Leung.   

Abstract

CAMA-1 cells, isolated from malignant pleural effusion, are grown in long-term cultures as monolayers. The rate of growth is dependent upon fetal bovine serum and estradiol. These cells also exhibit a dose response to added 17 beta-estradiol with respect to the incorporation of radiolabeled thymidine into cells. The uptake is increased at low levels of estradiol and decreased at pharmacological levels of estradiol. The uptake of uridine and leucine is also stimulated by estradiol in a dose-related manner. Induction of precursor uptake is not observable until cells have been exposed to estradiol for approximately 10 hr or longer. Cells plated for different periods in steroid-stripped serum remain sensitive to estrogenic stimulation and show similar lag time in response. Estrogenic effect is not noticeable in the absence of serum. Addition of prolactin can partially restore estrogenic stimulation of thymidine uptake in serum-free medium. Like other estrogen target tissues, these cells contain cytoplasmic and nuclear estrogen receptors. These results demonstrate that the CAMA-1 cell line is estrogen dependent and that these cells may provide a promising model for the in vitro investigation of the mode of estrogen action in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139610

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium.

Authors:  P Briand; O W Petersen; B Van Deurs
Journal:  In Vitro Cell Dev Biol       Date:  1987-03

2.  Collagen gel culture system and analysis of estrogen effects on mammary carcinogenesis.

Authors:  S Nandi; W Imagawa; Y Tomooka; M F McGrath; M Edery
Journal:  Arch Toxicol       Date:  1984-07       Impact factor: 5.153

3.  Identification of insulin-like growth factor binding proteins in breast cancer cells.

Authors:  D Yee; R E Favoni; M E Lippman; D R Powell
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

4.  8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer.

Authors:  M E Lippman; R B Dickson; S Bates; C Knabbe; K Huff; S Swain; M McManaway; D Bronzert; A Kasid; E P Gelmann
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

5.  Human tumor and normal tissue reactivity of the anti-(breast cancer) monoclonal antibody BA-Br-3 and its similarity to the anti-(epithelial membrane antigen) monoclonal antibody E29.

Authors:  S K Liao; R E Flahart; B Kimbro; L Horton; R K Oldham; J Hilgers; R van der Gaag
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines.

Authors:  A E Lykkesfeldt; P Briand
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

Review 7.  Mitogenic regulation of normal and malignant breast epithelium.

Authors:  M E Lippman; R B Dickson
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct

8.  DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.

Authors:  Marleen Ansems; Jonas Nørskov Søndergaard; Anieta M Sieuwerts; Maaike W G Looman; Marcel Smid; Annemarie M A de Graaf; Vanja de Weerd; Malou Zuidscherwoude; John A Foekens; John W M Martens; Gosse J Adema
Journal:  Breast Cancer Res Treat       Date:  2015-02-08       Impact factor: 4.872

9.  Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model.

Authors:  Vince Kornél Grolmusz; Jinfeng Chen; Rena Emond; Patrick A Cosgrove; Lance Pflieger; Aritro Nath; Philip J Moos; Andrea H Bild
Journal:  Cancer Cell Int       Date:  2020-06-17       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.